Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

HIV replication can be blocked by recombinant human interferon beta.

B Michaelis1, J A Levy

  • 1Cancer Research Institute, University of California, School of Medicine, San Francisco 94143.

AIDS (London, England)
|January 1, 1989
PubMed
Summary

Recombinant human interferon beta (rIFN-beta) effectively inhibits HIV replication in immune cells, especially at high doses. However, sustained treatment is necessary to prevent viral rebound and potential T-cell toxicity.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Not Available].

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]·2016
Same author

Atrial-septal-aneurysm-associated thrombus and stroke: Demonstration with transesophageal echocardiography.

Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association·2015
Same author

Life span of MRL/lpr/lpr mice.

Immunology today·2014
Same author

Dietary regulation of the autoimmune process in murine lupus.

Immunology today·2014
Same author

HIV-related symptoms and patient clusters among Chileans living with HIV.

AIDS care·2012
Same author

Virus-host interactions in HIV pathogenesis: directions for therapy.

Advances in dental research·2011

Area of Science:

  • Immunology
  • Virology
  • Pharmacology

Background:

  • Human immunodeficiency virus (HIV) infects peripheral mononuclear cells.
  • Interferon beta (IFN-beta) is a cytokine with antiviral properties.

Purpose of the Study:

  • To investigate the efficacy of recombinant human interferon beta (rIFN-beta) in reducing HIV replication.
  • To determine the optimal concentration and maintenance requirements for rIFN-beta treatment.
  • To assess the potential of rIFN-beta in treating HIV infection and T-cell malignancies.

Main Methods:

  • Culturing peripheral mononuclear cells infected with HIV.
  • Treating infected cells with varying concentrations of rIFN-beta.
  • Monitoring HIV replication and cell viability.

Related Experiment Videos

Main Results:

  • rIFN-beta significantly reduced HIV replication in a dose-dependent manner.
  • High concentrations of rIFN-beta (>100 units/ml) were required for maximal effect.
  • Cessation of rIFN-beta led to a resurgence of HIV production.
  • High rIFN-beta concentrations exhibited cytotoxicity towards transformed T cells.

Conclusions:

  • rIFN-beta demonstrates potent anti-HIV activity in vitro.
  • Sustained administration of high-dose rIFN-beta is crucial for sustained viral suppression.
  • The cytotoxic effect on T cells suggests potential therapeutic applications in T-cell malignancies.
  • rIFN-beta may be a viable treatment option for HIV infection with manageable side effects.